![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NIH Seeks Partner to Develop Safer Ketamine Treatment for Depression
NIH Seeks Partner to Develop Safer Ketamine Treatment for Depression
November 9, 2016
The federal government is looking for a partner to collaborate on developing a new treatment for anxiety and depression based on a chemical by-product produced when the body breaks down the drug ketamine.
Researchers from the National Institutes of Health and the University of Maryland at Baltimore are seeking a partner with expertise in preclinical development, IND filings and the ability to support clinical trials aimed at regulatory approval.
Ketamine has been clinically available for over 40 years as a general anesthetic; however, it can also be highly addictive and can cause severe side effects. In low, intravenous doses, ketamine has shown strong, rapid efficacy in treating the symptoms of depression.
Upcoming Events
-
21Oct